Pharmacosmos   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Holbaek Denmark (1965)
Status: No NME R&D (1965)

Organization Overview

First Clinical Trial
2007
NCT00536666
First Marketed Drug
2020
ferric derisomaltose (Monoferric)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pharmacosmos A/S | PHARMACOSMOS AS | Pharmacosmos A/S, Roervangsvej 30, DK 4300 Holbaek, Denemark | Pharmacosmos Therapeutics, Inc. | Pharmacosmos UK Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Anemia, Iron-Deficiency (Phase 4)

Colorectal Neoplasms (Phase 4)

Deficiency Diseases (Phase 3)

Esophageal Neoplasms (Phase 4)

Heart Failure (Phase 3)

Hematologic Diseases (Phase 1)

Hemorrhage (Phase 3)

Hypophosphatemia (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Intestinal Diseases (Phase 3)

Iron Metabolism Disorders (Phase 1)

Kidney Diseases (Phase 3)

Metabolic Diseases (Phase 1)

Neoplasms (Phase 3)

Postpartum Hemorrhage (Phase 3)

Psychomotor Agitation (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Restless Legs Syndrome (Phase 2)

Stomach Neoplasms (Phase 4)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 14